AB0916 ASSESSMENT OF PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAID-12) QUESTIONNAIRE FOR EVALUATIONS OF 6-YEARS TREAT-TO-TARGET STRATEGY OUTCOMES
Authors: P. Tremaskina, E. Loginova, L. Vorobyova, T. Korotaeva, M. Chamurlieva, S. Glukhova, A. Lila
Journal: Annals of the Rheumatic Diseases (2022)

Background The 12-item psoriatic arthritis impact of disease questionnaire (PSAID-12) have been found to be a reliable instrument to specifically assess the impact of psoriatic arthritis (PsA) for the patients (pts) as well as predictive of long-term outcomes [1]. There are no data about use of the PsAID-12 for evaluation of long-term outcomes of treat to target (T2T) strategy in PsA pts. Objectives to assess the PSAID-12 for evaluations of 6-years outcomes of T2T strategy in PsA. Methods 50 (M/F–24/26) PsA pts fulfilling CASPAR criteria were included. Mean age 45±12.1 yrs, median (Me) PsA duration 82 [66;97] month (mos), Me follow-up 72 [58;89] mos. At the early stage (PsA duration≤2 yrs) all pts were treated according to T2T study within 24 mos. At 6 years follow-up all pts underwent standard clinical examination (tender joint count (TJS), swollen joint count (SJC), patient global assessment disease activity (PtGA), CRP (mg/l), skin psoriasis (PsO) by BSA (%), presence of nail PsO, enthesitis dactylitis, DAPSA and completed PsAID-12. PsAID-12 score≤ 4 is considered as a “patient-acceptable status symptoms” (PASS). PsAID-12 &gt; 4 is considered as worse quality of life. DAPSA remission (REM-DAPSA) ≤4 and low disease activity (LDA) ≤14, moderate activity (Mo)≤28, high activity &gt;28 were calculated. Me [Q25-Q75], M±SD, Spearman’s correlation, Mann-Whitney test were performed. All p&lt;0.05 were considered to indicate statistical significance. Results At 6 yrs follow-up REM-DAPSA were seen in 17 out of 50 pts (34%), LDA in 15 out of 50 (30%) pts. Mean total PsAID-12 score was 2.62±2.1. PASS was seen in 38 out of 50 pts (76%). PsAID-12 significantly associated with the PsA activity parameters: TJC (r=0.73, p&lt;0.05), SJC (r=0.55, p&lt;0.05), PtGA (r=0.77, p&lt;0.05), CRP (r=0.55, p&lt;0.05) and DAPSA (r=0.75, p&lt;0.05). PsAID&gt;4 significantly correlated with presence of dactylitis (r=0.33, p&lt;0.05), skin severity (BSA&gt;3) and presence nails PsO (r=0.41/r=0.38) accordingly. In pts with REM/LDA by DAPSA total PsAID score was significantly lower compare to pts with Mo/High activity - 1.34±0.99 and 4.89±1.84, accordingly (p&lt;0.0001). All pts with REM/LDA status is achieved PASS by PsAID. Conclusion In our clinical practice PsAID-12 associated with joint and skin severity in PsA pts. PsAID-12 is useful instrument for evaluating of the long-term T2T outcomes, including REM/LDA by DAPSA. References [1]Queiro, R., Cañete, J.D., Montoro, M. et al. Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study. Arthritis Res Ther 22, 82 (2020) Disclosure of Interests Polina Tremaskina: None declared, Elena Loginova Speakers bureau: Janssen, Lyubov Vorobyova: None declared, Tatiana Korotaeva Speakers bureau: Pfizer, MSD, AbbVie, Novartis-Sandoz, JSC Biocad, Janssen, UCB, Lilly, Maria Chamurlieva: None declared, Svetlana Glukhova: None declared, Alexander Lila: None declared